Holen Sie sich die Stockscreener-App
57.94
2.90%
-1.73
Schlusskurs vom Vortag:
$59.67
Offen:
$60.2
24-Stunden-Volumen:
216.87K
Relative Volume:
1.02
Marktkapitalisierung:
$1.21B
Einnahmen:
$486.82M
Nettoeinkommen (Verlust:
$18.78M
KGV:
70.66
EPS:
0.82
Netto-Cashflow:
$100.45M
1W Leistung:
-1.66%
1M Leistung:
-0.70%
6M Leistung:
-5.56%
1J Leistung:
+0.54%
1-Tages-Spanne:
$57.39
$60.22
1-Wochen-Bereich:
$57.39
$60.54
52-Wochen-Spanne:
$52.50
$70.81
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(218) 634-3500
Adresse
210 MAIN STREET WEST, BAUDETTE, MN
Vergleichen Sie ANIP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
57.94 | 1.21B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
ANI Pharmaceuticals (ANIP) Expected to Post Earnings on Friday - Defense World
ANI Pharmaceuticals to Present at Raymond James’ - GlobeNewswire
ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March - The Manila Times
Inside Access: ANI Pharmaceuticals Sets Stage for Dual Healthcare Conference ShowcaseKey Dates for Investors - StockTitan
ANI Pharmaceuticals (ANIP) Shares Cross Above 200 DMA - Nasdaq
Ani Pharmaceuticals Sr. VP sells $23,816 in stock By Investing.com - Investing.com Canada
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year - GlobeNewswire
ANI Pharmaceuticals, Inc. to Release Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025 - Nasdaq
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET - The Manila Times
ANI Pharmaceuticals Earnings: Rare Disease Portfolio Performance and 2025 Growth Strategy Revealed - StockTitan
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? - Yahoo Finance
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? - Yahoo Finance
Legato Capital Management LLC Takes $334,000 Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of “Buy” by Analysts - Defense World
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of "Buy" by Analysts - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group - Financial Content
abrdn plc Makes New $13.16 Million Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals: More Than Just A Generics Company (NASDAQ:ANIP) - Seeking Alpha
ANI Pharmaceuticals (NASDAQ:ANIP) Rating Increased to Hold at StockNews.com - MarketBeat
Pacer Advisors Inc. Sells 566,516 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals Shares Strategic Insights at Conference - TipRanks
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Holdings Decreased by Pacer Advisors Inc. - Defense World
ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded to “Hold” at StockNews.com - Defense World
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Significant Decline in Short Interest - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
9,843 Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Bought by SG Americas Securities LLC - Defense World
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is ANI Pharmaceuticals (ANIP) Stock Undervalued Right Now? - Nasdaq
Investing in ANI Pharmaceuticals (NASDAQ:ANIP) three years ago would have delivered you a 53% gain - Yahoo Finance
StockNews.com Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) to Sell - Defense World
ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference - GlobeNewswire
ANI Pharma CEO Reveals Future Strategy: Key Insights Coming at Major Biotech Event - StockTitan
ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis - MarketBeat
Clostridium Difficile Infection Treatment Market Size Worth US$ 2.28 Billion by 2034 at a CAGR Of 6.3% | Fact.MR Report - GlobeNewswire
Millennium Management LLC's Strategic Acquisition in ANI Pharmac - GuruFocus.com
ANI Maintains Course With Rare Disease Push In 2025 - News & Insights
Wedge Capital Management L L P NC Trims Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $77.71 - MarketBeat
Gastroparesis Drugs Market to Grow by USD 1.34 Billion (2025-2029), Driven by Rising Global Diabetes Burden, AI's Role in Market TransformationTechnavio - Yahoo Finance
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal - MSN
Short Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Declines By 8.5% - MarketBeat
Assenagon Asset Management S.A. Raises Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) delivers shareholders respectable 12% CAGR over 3 years, surging 6.2% in the last week alone - Simply Wall St
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now? - Yahoo Finance
ANI Pharma To Present At 43rd Annual J.P. Morgan Healthcare Conference; Webcast At 5:15 PM ET - Nasdaq
Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of Stock - MarketBeat
Ani Pharmaceuticals senior VP sells $21,568 in stock By Investing.com - Investing.com Nigeria
Ani Pharmaceuticals senior VP sells $21,568 in stock - Investing.com
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.23%
3.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):